Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Asset Writedowns and Impairment (2016 - 2025)

Historic Asset Writedowns and Impairment for Lexaria Bioscience (LEXX) over the last 8 years, with Q3 2025 value amounting to $213824.0.

  • Lexaria Bioscience's Asset Writedowns and Impairment changed N/A to $213824.0 in Q3 2025 from the same period last year, while for Aug 2025 it was $213824.0, marking a year-over-year change of. This contributed to the annual value of $247364.0 for FY2025, which is 32769.9% up from last year.
  • Per Lexaria Bioscience's latest filing, its Asset Writedowns and Impairment stood at $213824.0 for Q3 2025.
  • Lexaria Bioscience's Asset Writedowns and Impairment's 5-year high stood at $213824.0 during Q3 2025, with a 5-year trough of $717.0 in Q1 2021.